Pharmacogenomics (PGx)

PI-043 - ATORVASTATIN AS A CARDIOPROTECTIVE AGENT AGAINST CARFILZOMIB-INDUCED CARDIOTOXICITY IN HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES.

PI-045 - FREQUENCIES OF CLINICALLY ACTIONABLE POLYMORPHISMS, GENOTYPES, AND PHENOTYPES OF CYP2D6 AND CYP2C19 GENES IN THE CENTRAL INDIAN POPULATION WITH COMMON MENTAL DISORDERS

PI-047 - GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS ASSOCIATED WITH CARDIOVASCULAR ADVERSE EVENTS IN BREAST CANCER PATIENTS TREATED WITH AROMATASE INHIBITORS: RESULTS FROM THE ALL OF US.

PI-048 - GREATER METHOTREXATE EXPOSURE IN HSLCO1B1*14 TRANSGENIC MICE AS THE RESULT OF PHARMACOGENOMIC GUIDED-DOSING NORMALIZES THERAPEUTIC RESPONSE

PI-049 - IMPACT OF CYP2C19 AND CYP3A INHIBITORS ON CLOPIDOGREL CLINICAL EFFECTIVENESS IN CYP2C19 GENOTYPED PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN A REAL-WORLD SETTING.

PI-050 - INFLUENCE OF ALDH2 RS671 POLYMORPHISM ON ANTIBODY TITER AFTER INFLUENZA VACCINATION: A PROSPECTIVE OBSERVATIONAL STUDY

PT-008 - REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.

PII-042 - ANALYSIS OF A CLINICAL PROGRAM TO RETURN CLINICALLY ACTIONABLE PHARMACOGENETIC INFORMATION FROM GERMLINE DNA SEQUENCING DATA GENERATED IN MOLECULAR TUMOR BOARDS: WORKFLOW AND ESTIMATED COSTS

PII-044 - DEMOGRAPHICS AND UTILIZATION OF MEDICATIONS WITH PHARMACOGENETICS GUIDELINES IN THE TRIAL OF PREMPTIVE PHARMAGOGENETICS IN UNDERSERVED PATIENTS (TOPP UP)

PII-045 - DNA METHYLTRANSFERASE INHIBITORS REDUCE TRIPLE NEGATIVE BREAST CANCER CELL GROWTH THROUGH ENHANCED IMMUNE RESPONSE BY DOWNREGULATION OF ZNF101

PII-046 - GENETIC VARIANTS PREDICTIVE OF FEBRILE NEUTROPENIA DURING INDUCTION I IN PEDIATRIC ACUTE MYELOID LEUKEMIA PATIENTS

PII-048 - GENOME-WIDE ASSOCIATION STUDY OF CENTRAL NERVOUS SYSTEM MEDICATION-INDUCED ADVERSE DRUG REACTIONS AMONG A SUBSET OF PARTICIPANTS IN THE NIH ALL OF US RESEARCH PROGRAM

PII-052 - PRECISION MEDICINE IN PRACTICE: DEVELOPMENT OF AN AUTOMATED WARFARIN PHARMACOGENOMIC DOSING CALCULATOR EMBEDDED IN THE ELECTRONIC HEALTH RECORD.

LB-007 - GENETIC POLYMORPHISMS IN SLC5A2 ARE ASSOCIATED WITH CLINICAL OUTCOMES AND SGLT2I RESPONSE IN HEART FAILURE PATIENTS.

LB-008 - GENOTYPE-SPECIFIC SAFTEY PROFILES AND PHARMACOKINETICS OF CANNABIDIOL IN HEALTHY SUBJECTS

LB-009 - LEVERAGING CPIC LEVEL 1A PHARMACOGENOMICS INSIGHTS TO MITIGATE ADVERSE DRUG EVENTS IN OLDER ADULTS: EVIDENCE FROM VIRGINIA ALL-PAYER CLAIMS DATABASE 2016-2020.

TIP-002 - EVALUATION OF A PHARMACIST-LED PHARMACOGENETICS CONSULTATION SERVICE ON HEALTHCARE COSTS AND OUTCOMES.